
Blood pressure and dementia risk share surprising link, study suggests
In a large, randomized trial, researchers led by First Hospital of China Medical University discovered that 'intensive blood pressure control' resulted in a 15% reduced dementia risk among participants and a 16% reduced risk of cognitive impairment.
The study included 33,995 people in rural China aged 40 or older who had 'uncontrolled hypertension.'
The participants were divided into two groups.
One received 'usual care,' while the other was assigned to 'trained non-physician community healthcare providers' who prescribed 'titrated antihypertensive medications.'
For the latter group, the medications helped them achieve a systolic blood pressure goal of <130 mm Hg and a diastolic blood pressure goal of <80 mm Hg, according to the study findings in Nature Medicine.
'The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group,' the researchers wrote.
They were also less likely to experience 'serious adverse events.'
3 High blood pressure can impact brain health, according to a new study.
BillionPhotos.com – stock.adobe.com
This was one of the first large-scale, randomized, controlled effectiveness trials to demonstrate a 'significant reduction in all-cause dementia associated with lowering blood pressure,' the researchers concluded.
There were some limitations of the study, the article acknowledged, including the absence of baseline and follow-up cognitive assessments.
Dr. Bradley Serwer — an interventional cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company that offers cardiovascular and anesthesiology services to hospitals — said this study presents an 'intriguing approach' to addressing dementia in individuals with uncontrolled hypertension.
3 'The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group,' the researchers wrote.
LIGHTFIELD STUDIOS – stock.adobe.com
'Unlike studies performed in the United States, this study employed non-physicians to significantly reduce blood pressure in rural China through a 'cluster' blinding method,' Ohio-based Serwer, who was not involved in the study, told Fox News Digital.
'While the study can be subject to scrutiny, it raises a pertinent question: How crucial is modification of cardiovascular risk factors in the development of dementia?'
The primary medications used in the study to lower blood pressure were calcium channel blockers and angiotensin receptor blockers, Serwer noted.
'These commonly prescribed medications have been independently associated with a reduced risk of dementia, irrespective of the magnitude of blood pressure reduction they achieve,' he said.
3 Nearly 34,000 people in rural China over the age of 40 participated in the study.
wutzkoh – stock.adobe.com
'This raises the possibility that the lower rates of dementia observed may be attributed to other beneficial effects of the medications rather than solely to blood pressure reduction.'
To confirm the findings, Serwer said it would be beneficial to include baseline cognitive assessments of the patients and to identify the prevalence of Alzheimer's dementia within the communities.
'The most significant takeaway from this study is the profound importance of addressing blood pressure, cholesterol, smoking and sedentary lifestyles,' the cardiologist said.
'By prioritizing these factors, we not only aim to prevent heart attacks and strokes, but also strive to enhance overall quality of life.'
The study was supported by the National Key Research and Development Program of the Ministry of Science and Technology of China, Chinese Society of Cardiology Foundation, and the Science and Technology Program of Liaoning Province, China.
Fox News Digital reached out to the researchers for comment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Axios
16 minutes ago
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
Yahoo
5 hours ago
- Yahoo
Mental health urgent care now available to all in Clermont County
Almost everyone has been to an urgent care before for a medical problem. However, not many know about mental health urgent cares. We visited one location right in Clermont County. Solve the daily Crossword


Business Wire
8 hours ago
- Business Wire
Wellness Innercell Expands into Indonesian Home Shopping Market with Joint Care
CHANGWON, South Korea--(BUSINESS WIRE)-- Wellness Innercell, a cosmetics manufacturer and distributor of health functional food, announced that it will launch its flagship health supplement product, 'Joint Care,' on Indonesian home shopping channels starting this October. 'In addition to our ongoing exports to the U.S., we will focus on pioneering new markets in Southeast Asia, starting with Indonesia in the second half of this year.' Share According to the company, Joint Care addresses the side effects and cost burden often associated with conventional joint supplements. It helps relieve joint pain while supporting cartilage protection, nerve and muscle health, dental care, bone density improvement, enhanced physical performance, immune system function, and energy production. Certified by the Korean Ministry of Food and Drug Safety as a health functional food, it contains key active ingredients at the maximum daily allowable dosage and includes probiotics to promote digestive health. Leveraging a multi-formula technology, Joint Care combines a variety of functional ingredients into a single all-in-one tablet, offered in convenient PTP (Press-Through Package) form for easy carrying and consumption. 'In addition to our ongoing exports to the U.S., we will focus on pioneering new markets in Southeast Asia, starting with Indonesia in the second half of this year,' said Kang Ik-geun, CEO of Wellness Innercell. About Wellness Innercell Wellness Innercell is a Korea-based manufacturer and distributor specializing in cosmetics and health functional foods, dedicated to delivering innovative, science-backed solutions for better living. Leveraging advanced formulation technology and strict quality standards, Wellness Innercell aims to expand its global presence and provide trusted health products to consumers worldwide.